文献速递肿瘤 PET/CT核素与放射性配体治疗

用于预测前列腺癌复发且PSA<1 ng/ml患者68Ga-PSMA PET/CT阳性的列线图的预测准确性与临床获益:基于单机构数据库的外部验证

Predictive accuracy and clinical benefit of a nomogram aimed to predict 68Ga-PSMA PET/CT positivity in patients with prostate cancer recurrence and PSA < 1 ng/ml external validation on a single institution database.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2020-01-31

该研究对Rauscher等发表的预测根治性前列腺切除术后生化复发患者68Ga-PSMA-11 PET/CT阳性的列线图进行外部验证,纳入413例PSA 0.2–1 ng/ml的患者。外部队列总检出率为44%(原人群为64.7%),列线图预测准确性为64%(原模型为67%),最佳截断值为35%(AUC=0.61)。决策曲线分析显示当阈值概率>35%时列线图有临床净获益。

要点

  • 外部验证队列68Ga-PSMA-11 PET/CT总检出率为44%,原人群为64.7%。
  • PSA(OR 7.06,p<0.001)和持续ADT(OR 2.07,p=0.03)是PET/CT阳性的独立预测因素。
  • 列线图预测准确性64%(原模型67%),最佳截断值35%(AUC=0.61),阈值概率>35%时有临床净获益。

核心结论

  • 外部队列中列线图的预测准确性与原模型相似,均欠佳。
  • PSA和持续ADT被证实为阳性预测因素,列线图最佳截断值为35%。

研究设计与样本

  • 对Rauscher等发表的列线图进行外部验证,纳入413例根治性前列腺切除术后生化复发(连续两次PSA≥0.2 ng/ml)且PSA 0.2–1 ng/ml的前列腺癌患者。
  • 采用多变量逻辑回归模型评估68Ga-PSMA-11 PET/CT阳性预测因素,通过量化预测准确性和模型校准评估性能,使用约登指数确定最佳截断值,并用决策曲线分析量化临床价值。

主要发现

  • 外部队列68Ga-PSMA-11 PET/CT总检出率为44%,原人群为64.7%。
  • 多变量分析显示,68Ga-PSMA-11 PET/CT时的PSA(OR 7.06,p<0.001)和当时持续ADT(OR 2.07,p=0.03)是PET/CT阳性的唯独立预测因素。
  • 列线图预测准确性欠佳,外部队列为64%,原模型为67%。
  • 校准图显示一致性欠佳。
  • 预测68Ga-PSMA-11 PET/CT阳性的最佳列线图截断值为35%(AUC=0.61)。

关键数值与推荐

  • 列线图最佳截断值为35%(AUC=0.61)。
  • PSA的OR为7.06(p<0.001),持续ADT的OR为2.07(p=0.03)。
  • 外部队列预测准确性64%,原模型67%。
  • 外部队列检出率44%,原人群64.7%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To perform an external validation of a recently published nomogram aimed to predict positive 68Ga-PSMA-11 PET/CT in patients with biochemical recurrence (BCR) after radical prostatectomy (RP) by Rauscher et al. (Eur Urol 73(5):656-661, 2018). METHODS: Overall, 413 PCa patients with BCR after RP (two consecutive PSA ≥ 0.2 ng/ml) and PSA value between 0.2 and 1 ng/ml were included. A multivariable logistic regression model was produced to assess the predictors of positive 68Ga-PSMA-11 PET/CT results. The performance characteristics of the model were assessed by quantifying the predictive accuracy, according to model calibration. Yuden's index was used to find the best nomogram's cut-off. Finally, decision curve analysis (DCA) was implemented to quantify the nomogram's clinical value. RESULTS: In the external cohort, the overall detection rate of 68Ga-PSMA-11 PET/CT was 44% vs. 64.7% in the original population. At multivariate analysis, PSA at 68Ga-PSMA-11 PET/CT (OR: 7.06, p < 0.001) and ongoing ADT at time of 68Ga-PSMA-11 PET/CT (OR: 2.07, p = 0.03) were the only independent predictors of PET/CT positivity. The predictive accuracy of nomogram was suboptimal and comparable to that reported in the original model (64% vs. 67%, respectively). The calibration plot indicated suboptimal concordance. The best nomogram's cut-off to predict positive 68Ga-PSMA-11 PET/CT was 35% (AUC = 0.61). In DCA, the nomogram revealed clinical net benefit when the threshold probabilities of positive 68Ga-PSMA-11 PET/CT is > 35%. CONCLUSION: We assessed similar suboptimal predictive accuracies in the external cohort compared to the original one. PSA and ongoing ADT were confirmed as positive predictors, and the most informative nomogram cut-off resulted 35%.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Bianchi L, Borghesi M, Schiavina R, et al. Predictive accuracy and clinical benefit of a nomogram aimed to predict 68Ga-PSMA PET/CT positivity in patients with prostate cancer recurrence and PSA < 1 ng/ml external validation on a single institution database. Eur J Nucl Med Mol Imaging. 2020. PMID: 32006061. doi:10.1007/s00259-020-04696-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。